Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy
NCT03945318Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2019
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of zigakibart in IgA nephropathy (IgAN) (6 arms), sponsored by Novartis. Primary endpoints: Number of participants with Treatment Emergent Adverse Events and treatment-emergent serious adverse events up to 276 weeks, Change from baseline in systolic and diastolic blood pressure up to 276 weeks and 1 more. Started Apr 2019; status: completed.
02
Drugs
zigakibart
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT03945318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03945318.